diabetes, the Japan Diabetes Society (JDS) defined an HbA 1c level <6.9% (equivalent to a JDS value of 6.5% before 2010) [3] to be the criterion for "excellent" or "good" in preventing the development and progression of microangiopathy [4] .
The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) have released a consensus statement that recommends once-daily (QD) injection of basal insulin when initiating insulin therapy in patients with type 2 diabetes mellitus [5] . The International Diabetes Federation (IDF) Clinical Guidelines Task Force recommends three methods: QD injection of basal insulin, twice-daily (BID) injections of premixed insulin, and intensive therapy [6] . Similarly, in Japan, the Treatment Guide for Diabetes recommends three methods when initiating insulin therapy in patients with type 2 diabetes mellitus [4] .
Each of the aforementioned insulin preparations participating centers. All patients provided written informed consent.
Study design
This was a multicenter, open-label, non-randomized, post-marketing clinical study performed at 22 study sites in Japan. The study consisted of 4 periods: Lead-in Period (2 to 4 weeks), Period 1 (16 weeks), Period 2 (16 weeks), and Period 3 (16 weeks) .
After the start of LM50 injections, sulfonylurea doses were reduced to the lowest sustainable dose or discontinued. Also, α-glucosidase inhibitors and glinides were discontinued if possible. Other OADs were continued only at the same dose without discontinuation during the study period. When the investigator judged it necessary to do so to ensure the safety of the patient, however, dose titration or discontinuation of OADs was allowed but not regarded as a deviation. Addition of a new OAD was not permitted.
The treatment period was 48 weeks. Although a particular dosing algorithm was not used in this study, the investigators were instructed to individually control blood glucose levels between 80 to 130 mg/dL before meals, which is recommended by JDS [3] , to achieve an HbA 1c <6.9%. The regimen of the LM50 injection was changed every 16 weeks based on a patient's HbA 1c level. For Period 1, all patients started at 4 units/day before breakfast as QD injections of LM50. For Period 2, the regimen was changed from QD to BID (before breakfast and dinner) if a patient's HbA 1c level at Week 16 was 6.9% or above, or the QD regimen was continued if the value was <6.9%. For Period 3, the regimen was changed from BID to TID (before breakfast, lunch, and dinner) if a patient's HbA1c level at Week 32 was 6.9% or above, or the BID regimen was continued if the value was <6.9%.
The primary measure was the proportion of patients who achieved an HbA 1c level <6.9%, which is the target recommended by the JDS, at Week 48 of treatment. Secondary measures included the proportions of patients who achieved an HbA 1c level <6.9% at Weeks 16 and 32 of treatment; the proportions of patients who achieved an HbA 1c level <7.4% at Weeks 16, 32, and 48; and the proportions of patients by regimen who achieved HbA 1c levels <6.9% and <7.4% at Weeks 16, 32, and 48. Other secondary measures included changes in HbA 1c, fasting blood glucose, 7-point self monitoring blood glucose (SMBG) profiles, fasting C-peptide levels, fasting serum lipids, body weight, daily dose of insulin, and safety, and regimens has inherent advantages and disadvantages. For example, QD injection of basal insulin is easy and considered to be well accepted by patients at the time of treatment initiation, but only a limited number of patients can achieve strict glycemic control, and more frequent injections often become necessary [7] [8] [9] . Intensive insulin therapy (basal/bolus) sufficiently supplements additional insulin and basal insulin, and thus helps to achieve stricter glycemic control. This has proved to be effective in preventing the development and progression of chronic complications [2, 10] . However, since it requires multiple injections (4 times or more per day), there is evidence that this leads to deterioration in patients' quality of life, and many patients are hesitant about having multiple injections when insulin therapy is first initiated [11] . The use of multiple insulin preparations inherently increases the risk of medication error such as using the wrong insulin preparation or missing an injection at bedtime [12] . Therefore, a desirable therapeutic approach is one that enables insulin to be introduced easily and facilitates the stepwise intensification of insulin therapy when necessary.
This study evaluated the effectiveness of insulin lispro mix 50 (LM50) with a stepwise intensification from QD to three times daily (TID) in combination with oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus on oral therapy and inadequate glycemic control. The primary endpoint of this study was to determine the proportion of patients who achieved an HbA 1c level <6.9% (equivalent to a JDS value of 6.5% before 2010) [3] at Week 48 of treatment. This target HbA 1c level is comparable to the target for glycemic control set by the ADA (HbA 1c level <7.0%) [13] . The clinical trial was registered with ClinicalTrials.gov (trial registration number NCT 00971997).
materials and methods

Patients
The study participants were patients with type 2 diabetes mellitus, aged 20 to 80 years, with inadequate glycemic control [HbA 1c levels between 7.9% and 11.4%], and body mass index (BMI) of ≤35 kg/ m 2 . Participants must have been taking OADs for at least 90 days prior to the start of the study and no insulin therapy within 6 months prior to the study. The study protocol was carried out in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the Ethics Review Committees of the who discontinued the study. These patients were not, however, counted as patients achieving the goal even if their HbA 1c values at the time of discontinuation were <6.9%. Changes from baseline to endpoint in HbA 1c , blood glucose levels, C-peptide levels, fasting serum lipids, body weight, and laboratory values were analyzed by the univariate t-test for the null hypothesis. Circadian variability was calculated as the difference between the maximum and the minimum blood glucose values in SMBG profiles. All analyses were performed with SAS version 9.1.3 software (SAS Institute, Inc., Cary, NC, USA). All data are represented as mean ± SD at endpoint (Week 48) unless otherwise stated.
Results
Study participants
A total of 135 patients started Period 1 with the QD regimen (Fig. 1 ). Of these, 126 patients completed Period 1, 121 patients completed Period 2, and 116 patients completed Period 3. Nineteen patients disconincluding hypoglycemia. Hypoglycemia was defined as any hypoglycemic event in which a patient self-reported hypoglycemia-related signs and symptoms regardless of the relationship to treatment. Severe hypoglycemia was defined as any symptomatic hypoglycemic event with a blood glucose level <50 mg/dL that required assistance, or the use of oral carbohydrates, glucagon injection, or intravenous glucose to restore the blood glucose level [14] . Nocturnal hypoglycemia was defined as any hypoglycemic event that developed between bedtime and breakfast.
Statistical methods
Efficacy and safety analyses were conducted on the full analysis set. This set consisted of all patients receiving at least 1 dose of the study drug. The proportions of patients who achieved an HbA 1c level <6.9% at Weeks 16, 32, and 48 of treatment and the proportions of patients who achieved an HbA 1c level <7.4% at Weeks 16, 32, and 48 were provided with 95% confidence intervals. The analysis included the patients the study period. Also, the mean dose of sulfonylurea in the remaining patients decreased from 2.81 ± 1.68 mg at baseline to 2.04 ± 1.42 mg at endpoint (glimepiride equivalent [15] ). Since some patients also discontinued other OADs, the average number of OADs used by each patient decreased from 2.50 ± 0.82 at baseline to 1.74 ± 0.91 at endpoint. (Table 3) .
Glycemic control
Significant reductions of 7-point SMBG at each time point were observed in completers: -25 ± 55 mg/ dL before breakfast, -59 ± 88 mg/dL 2 hours after breakfast, -41 ± 73 mg/dL before lunch, -44 ± 85 mg/ tinued the study, and the most frequent reason for study discontinuation was physician decision (n=7) followed by patient decision (n=5). Final regimens of LM50 for the completers were 9 patients on the QD schedule, 21 patients on the BID schedule, and 86 patients on the TID schedule.
Baseline characteristics of the patients in the full analysis set (FAS) and completers by final regimen are shown in Table 1 All patients were being treated with OADs at baseline. The number of patients who used each OAD and the number of OADs used by each patient at baseline and endpoint are shown in Table 2 . Most (94.8%) patients who completed 48 weeks of study medication used sulfonylureas at baseline. However, approximately one third of the patients discontinued sulfonylureas during 
Characteristic features of patients responding to each LM50 regimen
The proportion of patients on QD regimens who achieved an HbA 1c level <6.9% at Week 16 was 6.7% (9/135 patients). Baseline characteristics in the patients on QD were significantly different from the other three groups. Seven of 9 patients were males; their DM duration was only 4.4 years, mean BMI was 27.1, and mean HbA 1c was 7.97% (Table 1 ). The lower prevalence of dL 2 hours after lunch, -40 ± 77 mg/dL before dinner, -56 ± 97 mg/dL 2 hours after dinner, and -57 ± 75 mg/dL at bedtime. The circadian variability based on the 7-point SMBG was significantly reduced from 162 ± 61 mg/dL to 131 ± 62 mg/dL (-29 ± 86 mg/dL, p=0.001) in completers.
C-peptide, serum lipids, body weight, BMI and insulin dose
From baseline to endpoint, fasting C-peptide decreased from 1.89 ± 0.81 ng/mL to 1.56 ± 0.95 ng/mL (-0.34 ± 0.74 ng/mL, p<0.001), and CPR Index (fasting C-peptide/FBG x 100) [16] also decreased from1.22 to 1.04 (-0.16, p=0.001). Regarding serum lipids, no statistically significant changes were observed in total cholesterol and triglycerides, but HDL-cholesterol slightly increased from 54.0 ± 12.8 mg/dL to 56.4 ± 14.2 mg/dL (+2.4 ± 8.7 mg/dL, p=0.002). Body weight increased from 66.6 ± 14.1 kg to 67.9 ± 14.6 kg (+1.3 ± Three patients discontinued the study due to myocardial infarction, brain contusion, or death, but investigators deemed that all adverse events were unrelated to the study medication. The myocardial infarction, which occurred in a 63-year-old male patient, was classified as moderate in severity. The brain contusion was the result of a car accident; of note, the patient was not experiencing hypoglycemia at the time of the accident. The cause of death in the third patient was categorized as worsening of chronic cardiac failure, which was observed as a complication at baseline. Treatment-emergent adverse events reported in at least 5% of patients were nasopharyngitis (32.6%, 44/135 patients); upper respiratory tract inflammation (8.9%, 12/135 patients); and diabetic retinopathy, constipation, fall, and contusion (5.9%, 8/135 patients, each).
Statistically significant increases/decreases were observed in serum creatinine measurement, red blood cell counts and serum alanine aminotransferase. Serum creatinine measurements increased from 0.72 ± 0.25 mg/dL to 0.80 ± 0.49 mg/dL (0.08 ± 0.30 mg/ dL, p=0.002). Red blood cell counts decreased from 468. 3 diabetic complications and higher fasting C-peptide level seems to reflect the shorter duration of diabetes. The 7-point SMBG profile in patients on QD was also different from other three groups and it showed relatively lower glycemic excursion after meals (Fig. 2) .
The proportion of patients on BID regimens who achieved an HbA 1c level <6.9% at Week 32 was 15.6% (21/135 patients), and the proportion of patients on TID regimens who achieved an HbA 1c level <6.9% at Week 48 was 7.4% (10/135 patients). When comparing baseline the 7-point SMBG profile in the patients on BID and TID, no significant difference was observed (Fig.  2) . However, the changes with time in the 7-point SMBG profile by treatment group showed relatively higher blood glucose excursion after lunch at 16 and 32 weeks in patients on TID [A] (Fig. 3) . Also, when changes were compared between the TID [F] and other treatment groups, blood glucose levels were higher overall in the TID [F] group (Fig. 3) .
Safety
At least one hypoglycemic episode was observed in 65.9% (89/135 patients) of patients, and the incidence of daytime (between breakfast and bedtime) and night time (between bedtime and breakfast) hypoglycemic episodes was 65.9% (89/135 patients, 521 episodes) and 5.9% (8/135 patients, 14 episodes), respectively. The incidence of severe hypoglycemic episodes during daytime and night time was 2.2% (3/135 patients, 4 episodes) and 0.7% (1/135 patients, 1 episodes), respectively. All five severe hypoglycemic episodes in three patients were observed in patients on TID [F] . was also reported in a multinational study including Caucasian, Hispanic, Black, and Asian patients with type 2 diabetes mellitus [20] . In the study, HbA 1c was improved from 9.5% to 7.6% at 24 weeks. The present study represents the first clinical trial to evaluate the efficacy and safety of LM50 by stepwise intensification of the insulin regimen from QD to BID and to TID at 16-week intervals for Japanese patients with inadequate glycemic control by OADs, who are characterized by impaired insulin secretion. 
Discussion
In individuals without diabetes, approximately half of daily insulin secreted is basal, and the remainder is postprandial [17] . In patients with type 2 diabetes mellitus being treated with basal plus prandial insulin, it has been suggested that the ideal ratio of basal to prandial should be approximately 1:1 [18] . LM50 is a premixed insulin analogue containing an ultra rapid-acting component and an intermediate-acting component in a 1:1 ratio. Thus, LM50 TID closely reflects the physiological pattern of insulin secretion and can be more convenient for patients than a separately dosed basal with bolus regimen, and it was reported that multiple injection therapy with LM50 might achieve glycemic control similar to that obtained by basal-bolus therapy [19] .
Stepwise intensification of the insulin regimen from QD to BID and to TID at 6-week intervals using LM50 Regarding the dose of insulin, the daily dose of LM50 BID in Japanese patients was 0.42 units/kg/day when switching from pre-mixed human insulin [23] and it was more than double the mean dose used by the BID group in the current study (0.19 units/kg/day). One of the primary reasons for the difference appears to be that concomitant use of OADs was not allowed in the previous study, whereas almost all patients used a sulfonylurea as a concomitant OAD in the current study.
In the present study, 65.9% of patients experienced hypoglycemic episodes, but the severity of the most of hypoglycemia episodes was mild to moderate. Gradual increase of insulin dose might have contributed to the lower incidence of severe hypoglycemic episodes. Also, all patients who achieved an HbA 1c level <6.9% did not experienced severe hypoglycemia in this study. That means strict glycemic control was not the cause of the incidence of severe hypoglycemia in the present study.
A limitation of the present study is the lack of a reference arm which limits the ability to evaluate the effectiveness of the treatment regimen. Also, we did not investigate which kind of insulin regimen would be most effective for the patients who could not achieve an HbA 1c level <6.9% by stepwise introduction of LM50. Intensive insulin therapy which allows adjustment of the basal/bolus insulin ratio might be more effective in some of these patients.
In recent years, long-acting insulin has often been used as an introductory insulin treatment as well as BID administration of biphasic insulin. However, long-acting insulin has limited effects in optimal glycemic outcomes. Also, when this therapy fails to achieve glycemic targets, the regimen must be changed to a complicated intensive therapy by adding another type of insulin. The results of the present study suggest that the sole use of LM50, which can be simply adjusted by increasing the number of injections from once to 3 times daily, can lower the psychological barriers to the complexity of insulin therapy. In addition, it could improve glycemic control and also provide a suitable regimen for Japanese patients with type 2 diabetes mellitus.
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When comparing the treatment groups, baseline characteristics in the patients on QD regimen were significantly different from the other groups. Younger age with shorter duration of diabetes, overweight, and lower HbA 1c and FBG levels were particular characteristics of those patients. Their 7-point SMBG profile was in accordance with the previous report that morning hyperglycemia tends to contribute to overall glycemic control in the patients with shorter duration of diabetes [22] . A QD regimen would be effective for those patients. Compared with other treatment groups, there were no significant differences in baseline 7-point SMBG profile. However, relatively higher blood glucose excursion after lunch was observed at 16 and 32 weeks in patients on TID [A] compared with patients on both BID and TID [F] . Also, blood glucose levels in the 7-point SMBG profile were higher overall in the TID [F] group, which apparently reflects the longer duration of diabetes and lower fasting C-peptide levels in this group. These findings would be informative references for considering insulin regimens for each patient.
